As biologic treatments are expensive and associated with some concerns regarding long-term
safety, investigator hypothesize that early tapering and then withdrawal of biological agent,
in an homogenous group of children with juvenile idiopathic arthritis achieving inactive
disease, is safe and not inferior to the maintenance of stable treatment intensity over 24
weeks. In addition, investigator also hypothesize that an earlier tapering of treatment is
associated with a better quality-of-life and a general cost saving effect. MRP8/14 will be
studied as a potential biomarker for the risk of relapse. A study for biologic agent,
anti-biologic agent antibodies and a pharmacogenomic approach will complete the research, as
pharmacokinetic study during withdrawal of biologic treatment are rare in children.